IDEAYA Biosciences, Inc. IDYA Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Aura Biosciences, Inc.AURA

$16.99M-7.9%

Tango TherapeuticsTNGX

$33.57M—

Eikon Therapeutics, Inc.EIKN

$254.83M—

ImmunomeIMNM

$3.69M-22.6%

Erasca, Inc.ERAS

$45.95M-9.6%

Nuvation BioNUVB

$3.63M-30.4%

FAQ

What is IDEAYA Biosciences, Inc.'s operating lease liabilities (total)?

IDEAYA Biosciences, Inc. (IDYA) reported operating lease liabilities (total) of $28.6M in Q1 2026.

How has IDEAYA Biosciences, Inc.'s operating lease liabilities (total) changed year-over-year?

IDEAYA Biosciences, Inc.'s operating lease liabilities (total) increased by 10.1% year-over-year, from $25.97M to $28.6M.

What is the long-term trend for IDEAYA Biosciences, Inc.'s operating lease liabilities (total)?

Over 5 years (2020 to 2025), IDEAYA Biosciences, Inc.'s operating lease liabilities (total) has grown at a 32.9% compound annual growth rate (CAGR), from $6.72M to $27.91M.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.